Fierce Pharma Asia—AZ-CSPC deal; FDA's American cell shipping ban; China's trial review acceleration plan
AstraZeneca has penned a drug discovery pact focused on chronic diseases with China's CSPC Pharma. The FDA has halted new trials that export U.S. individuals' living cells to China. Chinese regulators are proposing to shorten clinical trial review times for novel medicines. And more.
AstraZeneca has penned a drug discovery pact focused on chronic diseases with China's CSPC Pharma. The FDA has halted new trials that export U.S. individuals' living cells to China. Chinese regulators are proposing to shorten clinical trial review times for novel medicines. And more.
